Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

PRRT

  • You have access
    Quantitative 68Ga-DOTATATE PET/CT parameters for the prediction of therapy response in patients with progressive metastatic neuroendocrine tumors treated with 177Lu-DOTATATE
    Claudia Ortega, Rebecca KS Wong, Joshua Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Zhihui Amy Liu and Ur Metser
    Journal of Nuclear Medicine February 12, 2021, jnumed.120.256727; DOI: https://doi.org/10.2967/jnumed.120.256727
  • You have access
    Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC
    Elin Pauwels, Sofie Van Binnebeek, Vincent Vandecaveye, Kristof Baete, Hubert Vanbilloen, Michel Koole, Felix M. Mottaghy, Karin Haustermans, Paul M. Clement, Kristiaan Nackaerts, Eric Van Cutsem, Chris Verslype and Christophe M. Deroose
    Journal of Nuclear Medicine July 1, 2020, 61 (7) 1014-1020; DOI: https://doi.org/10.2967/jnumed.119.236935
  • You have access
    Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
    Else A. Aalbersberg, Daphne M.V. Huizing, Iris Walraven, Berlinda J. de Wit-van der Veen, Harshad R. Kulkarni, Aviral Singh, Marcel P.M. Stokkel and Richard P. Baum
    Journal of Nuclear Medicine September 1, 2019, 60 (9) 1259-1265; DOI: https://doi.org/10.2967/jnumed.118.224386
  • You have access
    Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
    Najeff Waseem, Carina Mari Aparici and Pamela L. Kunz
    Journal of Nuclear Medicine July 1, 2019, 60 (7) 882-891; DOI: https://doi.org/10.2967/jnumed.118.217851
  • You have access
    SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework
    Rudolf A. Werner, Lilja B. Solnes, Mehrbod S. Javadi, Alexander Weich, Michael A. Gorin, Kenneth J. Pienta, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven P. Rowe and Constantin Lapa
    Journal of Nuclear Medicine July 1, 2018, 59 (7) 1085-1091; DOI: https://doi.org/10.2967/jnumed.117.206631
  • You have access
    Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, M. Konijnenberg, B.L. Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning and Dik J. Kwekkeboom
    Journal of Nuclear Medicine March 1, 2018, 59 (3) 452-458; DOI: https://doi.org/10.2967/jnumed.117.189712
  • You have access
    Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days
    Heribert Hänscheid, Constantin Lapa, Andreas K. Buck, Michael Lassmann and Rudolf A. Werner
    Journal of Nuclear Medicine January 1, 2018, 59 (1) 75-81; DOI: https://doi.org/10.2967/jnumed.117.193706
  • You have access
    Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors
    Clément Morgat, Gaétan MacGrogan, Véronique Brouste, Valérie Vélasco, Nicolas Sévenet, Hervé Bonnefoi, Philippe Fernandez, Marc Debled and Elif Hindié
    Journal of Nuclear Medicine September 1, 2017, 58 (9) 1401-1407; DOI: https://doi.org/10.2967/jnumed.116.188011
  • You have access
    Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine
    Rachel Levine and Eric P. Krenning
    Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 3S-9S; DOI: https://doi.org/10.2967/jnumed.116.186502
  • You have access
    Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive?
    Uta Eberlein, Marta Cremonesi and Michael Lassmann
    Journal of Nuclear Medicine September 1, 2017, 58 (Supplement 2) 97S-103S; DOI: https://doi.org/10.2967/jnumed.116.186841

Pages

  • Next
  • 1
  • 2
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire